Modality
Small Molecule
MOA
GLP-1/GIP
Target
Tau
Pathway
Tau
PNHIPF
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
~Dec 2020
→ ~Mar 2022
Phase 3
Jun 2022
→ Nov 2026
Phase 3Current
NCT04217575
1,259 pts·IPF
2022-06→TBD·Completed
NCT05460053
900 pts·PNH
2022-07→2026-11·Recruiting
2,159 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-127mo awayPh3 Readout· PNH
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2026-11-12 · 7mo away
PNH
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04217575 | Phase 3 | IPF | Completed | 1259 | EFS |
| NCT05460053 | Phase 3 | PNH | Recruiting | 900 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| PST-2276 | Poseida | Approved | Aβ | |
| TER-5062 | Terns | Phase 2/3 | Tau |